Characteristics of the study cohort
| Characteristic . | Study cohort . | |||||
|---|---|---|---|---|---|---|
| Primary EBV infection . | EBV reactivation . | |||||
| Immunocompetent . | Immunocompromised Transplant recipients . | |||||
| Asymptomatic EBV-seropositive patients (N = 206) . | Adolescent/adult patients with IM (N = 412) . | Pediatric patients with IM (N = 166) . | Older patients (N = 28) . | Patients without PTLD (N = 144) . | Patients with EBV+PTLD (N = 36) . | |
| Female sex, No. (%) | 90 (43.6) | 181 (43.9) | 73 (43.9) | 11 (39.2) | 61 (42.4) | 14 (38.9) |
| Age, median (min-max), y | 22.5 (18-40) | 22.1 (15-35) | 5.8 (1-14) | 71.7 (60-92) | 37.8 (14-91) | 30.2 (14-74) |
| EBV status | ||||||
| EBV– RT-qPCR | Neg. | Pos. | Pos. | Pos. | Pos. | Pos. |
| VCA IgM | Neg. | Pos. | Pos. | Pos. | Pos. | Pos. |
| VCA IgG | Pos. | Pos. | Pos. | Pos. | Pos. | Pos. |
| EBNA IgG | Pos. | Neg. | Neg. | Pos. | Pos. | Pos. |
| Clinical diagnosis | None | IM∗ | IM∗ | Unspecific symptoms† | Unspecific symptoms† | EBV+PTLD |
| Transplantation type, No. (%) | ||||||
| HSCT | 15 (10.4) | 16 (44.4) | ||||
| SOT | 129 (89.6) | 20 (55.6) | ||||
| First EBV episode after transplantation, median (range), d | 90 (29-312) | |||||
| EBV+PTLD diagnosis after transplantation, median (range), d | 99 (35-302) | |||||
| PTLD type, No. (%) | ||||||
| Early lesions | 4 (11.1) | |||||
| Monomorphic B-cell PTLD | 21 (58.3) | |||||
| Polymorphic PTLD | 11 (30.6) | |||||
| Characteristic . | Study cohort . | |||||
|---|---|---|---|---|---|---|
| Primary EBV infection . | EBV reactivation . | |||||
| Immunocompetent . | Immunocompromised Transplant recipients . | |||||
| Asymptomatic EBV-seropositive patients (N = 206) . | Adolescent/adult patients with IM (N = 412) . | Pediatric patients with IM (N = 166) . | Older patients (N = 28) . | Patients without PTLD (N = 144) . | Patients with EBV+PTLD (N = 36) . | |
| Female sex, No. (%) | 90 (43.6) | 181 (43.9) | 73 (43.9) | 11 (39.2) | 61 (42.4) | 14 (38.9) |
| Age, median (min-max), y | 22.5 (18-40) | 22.1 (15-35) | 5.8 (1-14) | 71.7 (60-92) | 37.8 (14-91) | 30.2 (14-74) |
| EBV status | ||||||
| EBV– RT-qPCR | Neg. | Pos. | Pos. | Pos. | Pos. | Pos. |
| VCA IgM | Neg. | Pos. | Pos. | Pos. | Pos. | Pos. |
| VCA IgG | Pos. | Pos. | Pos. | Pos. | Pos. | Pos. |
| EBNA IgG | Pos. | Neg. | Neg. | Pos. | Pos. | Pos. |
| Clinical diagnosis | None | IM∗ | IM∗ | Unspecific symptoms† | Unspecific symptoms† | EBV+PTLD |
| Transplantation type, No. (%) | ||||||
| HSCT | 15 (10.4) | 16 (44.4) | ||||
| SOT | 129 (89.6) | 20 (55.6) | ||||
| First EBV episode after transplantation, median (range), d | 90 (29-312) | |||||
| EBV+PTLD diagnosis after transplantation, median (range), d | 99 (35-302) | |||||
| PTLD type, No. (%) | ||||||
| Early lesions | 4 (11.1) | |||||
| Monomorphic B-cell PTLD | 21 (58.3) | |||||
| Polymorphic PTLD | 11 (30.6) | |||||
EBNA, EBV virus nuclear antigen 1; HSCT, hematopoietic stem cell transplantation; max, maximum; min, minimum; Neg., negative; Pos., positive; RT-qPCR, real-time quantitative polymerase chain reaction; SOT, solid organ transplantation.
As defined by the triad of fever, lymphadenopathy, and tonsillitis.
Unspecific symptoms include fever, weight loss, lymphadenopathy, night sweats, or fatigue.